Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
IMPACT Study (Improving Measurements of Persistence on "ACtonel" Treatment)
- Conditions
- Osteoporosis
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00268632
Insulin Glargine in Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 534
- Registration Number
- NCT00268645
- Locations
- 🇹🇷
Sanofi-Aventis, Istanbul, Turkey
Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]
- Conditions
- Prostatic Neoplasms
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00268710
Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)
- Conditions
- Head and Neck Neoplasms
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 45
- Registration Number
- NCT00268671
FOCUS Fatigue Outcome in Copaxone USers
- First Posted Date
- 2005-12-20
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 111
- Registration Number
- NCT00267319
- Locations
- 🇨🇿
Sanofi-Aventis, Praha, Czech Republic
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder
- Conditions
- Anxiety Disorders
- First Posted Date
- 2005-12-19
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 366
- Registration Number
- NCT00266747
- Locations
- 🇸🇪
Sanofi-Aventis Administrative Office, Bromma, Sweden
Enoxaparin in Acute Venous Thromboembolic Disease
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2010-02-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 251
- Registration Number
- NCT00265993
- Locations
- 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey
Irbesartan in Hypertension
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 88
- Registration Number
- NCT00265967
- Locations
- 🇹🇷
Sanofi-Aventis, Istanbul, Turkey
TEDDY: Spores of Bacillus Clausii in Acute Diarrhoea in Children
- Conditions
- Diarrhea
- First Posted Date
- 2005-12-14
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 420
- Registration Number
- NCT00265369
- Locations
- 🇫🇷
Sanofi-Aventis, Paris, France
Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
- Conditions
- Inappropriate ADH SyndromeHyponatremia
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2009-01-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 57
- Registration Number
- NCT00264914
- Locations
- 🇨🇦
sanofi-aventis Canada, Laval, Canada
🇨🇭Sanofi-Aventis Administrative Office, Geneva, Switzerland